Technology explainer
How Phage-Based Nanovaccines Display Tumor Antigens
Engineered bacteriophages can carry repeated tumor-antigen fragments on their protein shells while their DNA supplies an immune-stimulating signal, creating a genetically programmable vaccine scaffold.
A phage-based nanovaccine uses a virus that normally infects bacteria as a nanoscale scaffold. Researchers modify genes for the phage coat so selected antigen fragments appear repeatedly on its surface.
Why repetition matters
Immune cells encounter many copies of the target in an organized pattern. Dendritic cells can take up the particle, process the antigen and present it to T cells. The number and spacing of displayed antigens can change that response.
A built-in immune signal
Some bacteriophages contain DNA motifs that activate innate immune receptors such as TLR9. This can give the carrier an adjuvant-like role in addition to transporting the antigen.
What personalization requires
For a personalized cancer vaccine, researchers must identify tumor-specific neoantigens, encode suitable fragments and manufacture a consistent particle. Animal results do not guarantee human safety or effectiveness, especially against established tumors.
First appeared in
A Phage Nanofiber Let Researchers Tune the Dose of a Cancer Antigen
